Key result
Glucose-insulin-potassium (GIK) therapy in the CREATE-ECLA trial yielded negative results, which the authors attribute to delayed initiation rather than a failure of the metabolic concept.
Why the study?
Does glucose-insulin-potassium (GIK) reduce mortality in patients with ST-elevation acute myocardial infarction?
Population
Patients with ST-elevation acute myocardial infarction (AMI)
Design
Editorial
Authors
Loading...
This editorial argues that despite the negative CREATE-ECLA trial, the metabolic approach of GIK in AMI should not be abandoned and future trials should test very early administration.
Does glucose-insulin-potassium (GIK) reduce mortality in patients with ST-elevation acute myocardial infarction?
This editorial argues that despite the negative CREATE-ECLA trial, the metabolic approach of GIK in AMI should not be abandoned and future trials should test very early administration.
Apstein et al. (2005) conducted an editorial in ST-elevation acute myocardial infarction (AMI) (n=20,201). Glucose-insulin-potassium (GIK) was evaluated. Glucose-insulin-potassium (GIK) therapy in the CREATE-ECLA trial yielded negative results, which the authors attribute to delayed initiation rather than a failure of the metabolic concept.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: